Tomorrow's Science For Today's Clinician
Xuanbai Chengqi decoction or XBCQ, a Chinese remedy used to treat COPD, was found in a mice model study that it potentially changes the gut microbiome to modulate immune cells, improve lung function and reduce lung inflammation.
The real worry now in the world is that breakthrough infections among the fully vaccinated have become much more common. While the protection supposedly assured by the two-dose course of the vaccination has been proven shaky with the new variant camouflaging with the help of an unusually large number of mutations, the worry is that it can break through human immune cells too to get into the DNA, causing organ damage and making the disease progress into a critically severe condition and turn fatal.
According to an analysis by scientists at the FDA, this experimental drug reduced the risk of hospitalization or death from COVID-19 only by about 30 percent compared to a placebo.
Socioeconomic status, age and gender in underserved communities are the key contributing factors that impact patients’ access to care in most of the markets, including India, the report said.
One of the biggest challenges India is going to face post Covid is a heavy burden of mental health cases,…
The disease incidence, which increases very rapidly in individuals above 35 years of age, accounts for 12.8 million DALYs, 6.7 million YLDs and 0.3 million deaths in the country.
The study report stated that across the whole population — including patients older than 65 years, patients who were obese (body-mass index ≥30 kg/m2), and those who had received corticosteroid — IVIG had no effect on the duration of invasive mechanical ventilation and mortality.
Its prescription drugs and medical devices — two largest businesses — will be kept under the Johnson & Johnson name, while the company that will sell the consumer health products, including Neutrogena, Aveeno, Tylenol, Listerine, Johnson’s, and Band-Aid and others, will have a new name.
As per the approval, the patient can start taking the medicine within five days of the symptom onset. Molnupiravir, is the first oral anti-viral drug that patients could take at home to ease symptoms and speed up recovery.
The study, which compliments all the previous research works on ‘Long Covid’ using self-reported confirmation of SARS-CoV-2 infection and online questionnaires to assess cognitive deficit, was the first one where all participants underwent in-person psychological testing to assess cognitive function.